Adjuvant systemic therapy for melanoma
Determining potential treatment benefits for melanoma patients receiving adjuvant interferon
Disclaimer: This tool is designed for use by doctors only. The results of the tool alone should
never be used to determine a patient's medical treatment. This tool is a statistical model and is not a substitute
for an individual treatment plan developed by a doctor with personal knowledge of a specific patient. Other important
factors that must be considered include the patient's own medical history, the patient's family medical history and
the experience, knowledge, and training of the doctor. Doctors should discuss these results in person with their
patients as part of their overall treatment recommendations and should not advise patients to access the tool on their own.
Please note that the potential benefits from adjuvant interferon are based on published data from the Eastern
Cooperative Oncology Group.
This tool was created exclusively for physician use by Drs. Stephan D. Thomé, Charles L. Loprinzi and Michael P. Heldebrant. It was introduced in their manuscript, "Determination of potential adjuvant systemic therapy benefits for patients with resected cutaneous melanomas" published in the September 2002 issue of the Mayo Clinic Proceedings.


Home 